[(1R)-3-(3,4-dimethoxyphenyl)-1-[3-(2-morpholin-4-ylethoxy)phenyl]propyl] (2S)-1-[(2S)-2-[3-(hydroxymethyl)-4,5-dimethoxyphenyl]butanoyl]piperidine-2-carboxylate

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: [(1R)-3-(3,4-dimethoxyphenyl)-1-[3-(2-morpholin-4-ylethoxy)phenyl]propyl] (2S)-1-[(2S)-2-[3-(hydroxymethyl)-4,5-dimethoxyphenyl]butanoyl]piperidine-2-carboxylate
• 化学式: C₄₂H₅₆N₂O₁₀
• 分子量: 748.9
• InChiKey: AVVCHAAFTAEEEY-QGBCWPEESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  54
• 可旋转键数：
  19
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  126
• 氢给体数：
  1
• 氢受体数：
  11

文献信息

• CONDITIONAL REPLICATING CYTOMEGALOVIRUS AS A VACCINE FOR CMV
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US20140220062A1

  公开（公告）日：2014-08-07

  The present invention relates to methods of inducing an immune response to cytomegalovirus (CMV) using a genetically modified CMV that is conditionally replication defective. The methods of the invention can be used to treat and/or prevent primary CMV infection, infection due to reactivation of a latent CMV and a super-infection of a different strain of CMV that had been previously encountered. The present invention also relates to a replication defective CMV which has been recombinantly altered to allow for external control of viral replication. Compositions comprising the replication defective CMV are also encompassed by the present invention.
• CONDITIONAL REPLICATING VIRAL VECTORS
  申请人：FU Tong-ming

  公开号：US20150307850A1

  公开（公告）日：2015-10-29

  The present invention relates to a cytomegalovirus (CMV) which has been recombinantly altered to express a heterologous polypeptide and to allow for external control of viral replication. The heterologous polypeptide may be a polypeptide of interest such as an antigen, antibody or immune modulator. The CMV vectors of the invention are replication defective, or chemically controllable replication capable, or replication competent. The present invention also relates to uses of the CMV vectors such as inducing an immune response to an antigen or expressing an antibody or immune modulator in vivo. Compositions comprising the CMV expressing the heterologous polypeptide are also encompassed by the present invention.
• US9546355B2
  申请人：——

  公开号：US9546355B2

  公开（公告）日：2017-01-17